Philips launches new Bridge Plus Occlusion Balloon to help manage rare but life-threatening SVC tears during lead extraction
Rhea-AI Summary
Royal Philips (NYSE: PHG) on April 23, 2026 launched the Bridge Plus Occlusion Balloon to help electrophysiology teams manage rare superior vena cava (SVC) tears during transvenous lead extraction. Bridge Plus deploys in under two minutes, can reduce blood loss by up to 90%, and maintains hemostasis for at least 30 minutes. The device builds on Bridge technology used in more than 50,000 U.S. procedures and is commercially available in the United States; broader international availability is expected later in 2026, pending registrations.
Positive
- Deployment under two minutes (average 58.33 seconds in test)
- Up to 90% reduction in blood loss reported in animal model
- Maintains hemostasis for at least 30 minutes
- Now commercially available in the United States
Negative
- International availability pending country registrations (expected later in 2026)
- Key effectiveness claim based on an animal model, not exclusively human trials
- Deployment timing evidence from small sample (n=6) tests
Key Figures
Market Reality Check
Peers on Argus
PHG is down 0.84% while key medical device peers like STE, DXCM, PODD, and SNN show modest gains between 0.40% and 0.89%, indicating today’s move is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | CT platform clearance | Positive | -0.8% | FDA 510(k) clearance for Rembra CT/RT platform enabling faster CT imaging. |
| Apr 16 | AI CT clearance | Positive | -1.6% | FDA 510(k) clearance for AI-powered Philips Spectral CT Verida system. |
| Apr 02 | Governance/leadership | Positive | -0.7% | Philips Chief Medical Officer appointed to MDIC Board of Directors. |
| Mar 26 | Cardiology AI clearance | Positive | -1.1% | FDA 510(k) clearance for EchoNavigator R5.0 with AI DeviceGuide for M-TEER. |
| Mar 25 | Cardiology product launch | Positive | +2.7% | Launch of IntraSight Plus interventional cardiology platform with FDA and CE marks. |
Recent positive regulatory and product news has often been followed by mild negative price reactions.
Over the past month, Philips reported multiple innovation milestones, including FDA 510(k) clearances for its Rembra CT platform on Apr 22, 2026 and the AI-powered Verida spectral CT on Apr 16, 2026, plus an AI-guided heart valve repair solution on Mar 26, 2026. It also launched the IntraSight Plus cardiology platform on Mar 25, 2026 and announced a leadership-related MDIC board appointment on Apr 2, 2026. Despite generally positive news, four of these five events were followed by negative 24-hour price moves.
Market Pulse Summary
This announcement highlights Philips’ launch of Bridge Plus, an advanced occlusion balloon for managing rare but life‑threatening superior vena cava tears during lead extraction. The device builds on technology used in more than 50,000 procedures and is designed to cut blood loss by up to 90% and maintain hemostasis for around 30 minutes. In context of recent imaging and cardiology product clearances, this reinforces Philips’ focus on complex interventional care; investors may watch adoption trends and clinical data updates over time.
Key Terms
hemostasis medical
fluoroscopy medical
510(k) clearance regulatory
AI-generated analysis. Not financial advice.
April 23, 2026
- Bridge Plus was designed for rare, life-threatening emergencies to help control bleeding during superior vena cava (SVC) tears, which occur in <
0.5% of lead extraction procedures [1] but require immediate intervention - Bridge Plus allows for rapid response when every second counts by deploying in under two minutes [2] and stopping up to
90% blood loss [3], helping stabilize patients with 30 minutes of hemostasis [4] - Bridge Plus was built upon proven Bridge Occlusion Balloon technology, used in more than 50,000 U.S. procedures [5,*], with evidence showing improved survival when staged in advance [6,**]
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced the launch of the next-generation Bridge Plus Occlusion Balloon, designed to help electrophysiology teams rapidly control bleeding and stabilize patients during rare but life-threatening superior vena cava (SVC) tears in transvenous lead extraction (TLE) procedures. Building on technology used in more than 50,000 procedures [5*], Bridge Plus enables electrophysiology teams to respond in minutes – helping stabilize patients and buy critical time for surgical repair [2-4].
Lead extraction procedures are commonly performed to remove leads from cardiac implantable electronic devices (CIEDs), such as pacemakers or defibrillators, due to damaged, infected or malfunctioning leads. While there is evidence of lead extraction’s safe use [7,8], SVC tears, occurring in fewer than
Bridge Plus is designed to provide temporary vessel occlusion, helping reduce blood loss, maintain hemostasis, and stabilize patients during emergencies. The balloon can deploy in less than two minutes [2], stop up to
“Ensuring procedural safety is a top priority for electrophysiology teams,” said Stacy Beske, Business Leader, Image-Guided Therapy Devices at Philips. “Bridge Plus builds on established technology to help physicians prepare for rare SVC tears and respond quickly with the control needed to stabilize patients and transition to surgery.”
Clinical evidence highlights the importance of being prepared for this emergency scenario, with studies showing that survival rates in SVC tear events improved from
“Although superior vena cava tears are rare, they represent one of the most critical emergencies that can occur during lead extraction,” said Dr. Thomas Callahan, an electrophysiologist at Cleveland Clinic who studied the technology***. “Having an occlusion balloon staged and ready can significantly improve response time when every second matters. This technology may help teams prepare for these rare but serious events and support safer lead extraction procedures.”
Prophylactic balloon set up brings additional benefits during TLE procedures, including individualized balloon staging for each patient, and the ability to deploy Bridge Plus if fluoroscopy is no longer available.
Bridge Plus is a low-pressure, compliant occlusion balloon with radiopaque markers designed for accurate placement and compatibility with a wide range of patient anatomies [9]. The device expands Philips’ portfolio of lead management solutions supporting safe and effective extraction procedures.
The Bridge Plus Occlusion Balloon is now commercially available in the United States, with international availability expected later in 2026, pending country registrations. The solution will also be showcased at Heart Rhythm Society (HRS) 2026, taking place April 24-26 in Chicago, IL.
For more information, visit the Philips Bridge Plus Occlusion Balloon product page.
*Cases performed in United States since Bridge launch in 2016.
** When staging the Bridge Balloon versus when no Bridge balloon is used.
*** Dr. Callahan discloses consulting payments from Philips North America LLC for training and education services.
[1] Azarrafiy, Ryan et al. “Endovascular Occlusion Balloon for Treatment of Superior Vena Cava Tears During Transvenous Lead Extraction: A Multiyear Analysis and an Update to Best Practice Protocol.” Circulation. Arrhythmia and electrophysiology vol. 12,8 (2019): e007266. doi:10.1161/CIRCEP.119.007266.
[2] Document on file D002023609_A_Bridge M&M Marketing Claims Test Report. Average timed deployment for commercial Bridge was 74.33 seconds (n=6) and Bridge Plus was 58.33 seconds (n=6).
[3] Document on File, D027561 Marketing claims blood loss report for Bridge project 1338 - When deployed, the Bridge Occlusion Balloon reduces blood loss of an SVC tear by
[4] Document on file, D026197 & animal study - NGX028-IS17 - All animals had biological metrics measured for up to 45 minutes during occlusion and 15 minutes post device deployment.
[5] Document on file. LT-002760 Bridge Sales Customers Raw Data.
[6] Bruce L. Wilkoff, MD, FHRS, Roger G. Carrillo, MD, MBA, FHRS, Ryan Azarrafiy, BA, Darren C. Tsang, BS, Thomas A. Boyle, BS. Compliant endovascular balloon reduces the lethality of superior vena cava tears during transvenous lead extractions.
[7] Wazni 0, Epstein LM, Carrillo RG, et al. Lead extraction in the contemporary setting: the LExlCon study: an observational retrospective study of consecutive laser lead extractions. J Am Coll cardiol. 2010;55(6):579-586.
[8] Bongiorni MG, Kennergren C, Butter C, et al. The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) registry of transvenous lead extraction outcomes. Eur Heart J. 2017;38(40):2995-3005.
[9] Document on file, D026203 Engineering Translation Rationale For Bridge, Project #1338 – PR00. The balloon will cover the length and diameter of the SVC in
For further information, please contact:
Joost Maltha
Philips Global External Relations
Tel.: +31 610 558 116
E-mail: joost.maltha@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
- Clinical illustration of the Philips Bridge Plus balloon in use
- The Philips Bridge Plus Balloon, uninflated prior to use
- The inflated Philips Bridge Plus Balloon
